Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.

Item
http://www.wikidata.org/entity/Q37604504
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Canakinumab for the treatment of familial Mediterranean fever.The burgeoning field of innate immune-mediated disease and autoinflammation.Interleukin-1 Blockade: An Update on Emerging Indications.Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.Autoinflammatory Diseases with Periodic Fevers.Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome.Tumor necrosis factor-associated periodic syndrome in adults.TNF-α potentiates uric acid-induced interleukin-1β (IL-1β) secretion in human neutrophils.Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.The classification, genetic diagnosis and modelling of monogenic autoinflammatory disordersIL-6, IL-17 and Stat3 are required for auto-inflammatory syndrome development in mouse
P2860

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.

Item
http://www.wikidata.org/entity/Q37604504
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
Canakinumab treatment for pati ...... an open-label, phase II study.
@nl
type
label
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
Canakinumab treatment for pati ...... an open-label, phase II study.
@nl
prefLabel
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
Canakinumab treatment for pati ...... an open-label, phase II study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Canakinumab treatment for pati ...... an open-label, phase II study.
@en
P2093
P2860
P304
P31
P356
10.1136/ANNRHEUMDIS-2015-209031
P407
P433
P478
P50
P577
P698
P921
P932